Business Model Breakdown
How Protalix Biotherapeutics Inc Makes Money
PLX
Market Cap
$162M
Annual Revenue
$76M
Profit Margin
20.1%
Employees
213
The Short Version
Protalix Biotherapeutics is a pharmaceutical company that develops and commercializes recombinant therapeutic proteins for rare diseases, primarily using its proprietary ProCellEx plant cell-based protein expression system. The company primarily generates revenue through licensing fees, milestone payments, and a share of product sales from its lead drug, Elfabrio (pegunigalsidase alfa), which treats Fabry disease. It partners with larger pharmaceutical companies, such as Chiesi Global Rare Diseases, for the global commercialization and distribution of its approved products, enabling it to focus on drug development while leveraging a partner's extensive market reach.
Where the Revenue Comes From
Product Sales/Royalties from Elfabrio (~60-70% of 2026 projected non-milestone revenue)
Milestone Payments from Chiesi (~30-40% of 2026 projected non-milestone revenue if including future milestones)
Who buys: Chiesi Global Rare Diseases (primary commercialization partner), ultimately Fabry disease patients and healthcare providers globally.
Why It Works (Competitive Advantages)
- ✔Proprietary ProCellEx plant cell-based protein expression system, potentially offering production advantages and specific therapeutic benefits (e.g., reduced immunogenicity).
- ✔Strategic global partnership with Chiesi for commercialization, providing extensive reach and resources.
Economic Moat: Narrow (Intangible Assets/IP (ProCellEx platform, Elfabrio patents and regulatory approvals), Switching Costs (for patients already on Elfabrio, potential for better tolerability compared to enzyme replacement therapies))
What Our Analysis Says
DVR Score as of June 11, 2026
Protalix (PLX) continues to exhibit strong potential for 10x growth, building on its recent financial turnaround. The stellar Q1 2026 performance, with $18.3 million net income and $0.22 GAAP EPS (as noted in prior analysis and consistent with current P/E), substantially de-risks profitability concerns. The reaffirmed 2026 revenue guidance of $78–$83 million, backed by the $25 million Chiesi milestone and strong Elfabrio sales, solidifies revenue trajectory. The proprietary ProCellEx platform and the strategic global partnership with Chiesi for Elfabrio provide a significant competitive moat in the rare disease market. While dependency on milestone payments and sustained Elfabrio organic growth are key risks, the dramatic shift to profitability and analyst conviction (average target $11.00) indicate strong positive momentum and a compelling re-rating opportunity.